House Bill 592, titled the Toxic-Free Medical Devices Act of 2025, aims to prohibit the manufacturing, selling, and distributing of intravenous solution containers and intravenous tubing that contain intentionally added di(2-ethylhexyl) phthalate (DEHP). The bill recognizes DEHP as a toxic chemical that poses significant health risks, including endocrine disruption, reproductive health issues, and potential carcinogenic effects. The legislation sets specific deadlines for compliance, with intravenous solution containers banned starting January 1, 2030, and intravenous tubing banned by January 1, 2035. Additionally, it establishes penalties for violations and outlines exemptions for certain medical products.
If enacted, this bill will amend Chapter 130A of the North Carolina General Statutes, introducing a new article focused on DEHP hazard management. It will significantly impact manufacturers and distributors of medical devices, requiring them to eliminate DEHP from their products by the specified deadlines. The bill aims to enhance public health protections by reducing exposure to harmful substances in medical devices, thereby aligning state laws with growing concerns over the safety of medical products.
The general sentiment surrounding House Bill 592 appears to be supportive among health advocates and environmental groups, who emphasize the importance of reducing toxic substances in medical devices. However, there may be concerns from manufacturers regarding the feasibility of compliance within the set timelines, particularly related to the development of alternative materials and the potential economic impact of the changes.
Notable points of contention include the timeline for compliance and the potential economic burden on manufacturers who may struggle to meet the deadlines for transitioning to DEHP-free products. Some stakeholders argue that the deadlines may be too aggressive, while proponents of the bill stress the urgency of addressing the health risks associated with DEHP exposure. Additionally, the bill's prohibition on replacing DEHP with other ortho-phthalates has raised questions about the availability of safe alternatives.